Researchers are launching a new clinical trial to evaluate whether intranasal insulin—a nasal spray form of the well-known diabetes medication—can be safely used by individuals who have experienced a spinal cord injury. This early-stage study represents a hopeful first step toward exploring new, non-invasive therapeutic options for a population that currently has limited treatment avenues for injury-related complications.
Insulin nasal spray has already demonstrated a favorable safety profile in other patient populations, including studies exploring its effects on cognitive and metabolic health. However, its use in people with spinal cord injury has not yet been tested, making this trial an important foundational effort. By focusing first on safety and feasibility, the research team is taking a careful, methodical approach that could pave the way for larger studies down the line.
The trial will enroll up to 12 participants who sustained a spinal cord injury at least four months prior, allowing time for their condition to stabilize before testing begins. Over a 24-day period, participants will self-administer either a 76 IU insulin nasal spray or a placebo at home, with support from a study partner if needed. Throughout the trial, participants will undergo regular health assessments and blood draws, helping researchers closely monitor safety and tolerability.
What makes this study particularly encouraging is its emphasis on accessibility and real-world use. Because the treatment is administered at home rather than in a clinical setting, the trial design reflects a practical, patient-centered approach that could make future treatments more convenient if the therapy proves effective. Additionally, using an already-approved medication in a new delivery form and application may help streamline future research and potential development timelines.
While this study is focused solely on establishing safety and feasibility, it lays important groundwork for future research into whether intranasal insulin could offer meaningful benefits for people recovering from spinal cord injuries. As with all early-phase clinical research, results will need to be confirmed through further studies before any conclusions about effectiveness can be drawn. This post is for informational purposes only and is not intended as medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Source: Clinical Trial: Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury
Leave a Reply